drugset

drugset / Trial / NCT05943041

Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer

NCT05943041 ↗

Phase 1 Completed 9 enrolled GILongevity

Non-randomizedSequentialOpen-labelTreatment

Summary

Prospective, open label, multi-dose, sequential dose escalation, single-center, Phase 1 trial

Timeline

Start: 2023-04-28
Primary completion: 2023-12-22
Completion: 2023-12-22

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GB104	Other / unclassified	—	Oral

Indications